Bicycle Therapeutics Plc

Research Bicycle Therapeutics Plc (BCYC) on Bullrun: market cap USD 221.15M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 221.15M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 72.59M-USD 218.96M-USD 252.03Mn/a-3.16USD 628.11MUSD 16.85MUSD 609.98M
FY2024USD 35.28M-USD 169.03M-USD 165.96Mn/a-2.9USD 879.52MUSD 9.49MUSD 793.06M
FY2023USD 26.98M-USD 180.66M-USD 63.56Mn/a-5.08USD 526.42MUSD 30.70MUSD 370.93M
FY2022USD 14.46M-USD 112.72M-USD 105.10Mn/a-3.8USD 339.15MUSD 30.32MUSD 270.78M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 221.15Mn/an/an/a
20252025-12-31USD 491.12Mn/an/an/a
20242024-12-31USD 966.86Mn/an/an/a
20232023-12-29USD 766.98Mn/an/an/a
20222022-12-30USD 878.81Mn/an/an/a
20212021-12-31USD 1.80Bn/an/an/a

About Bicycle Therapeutics Plc

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. The company's products pipeline include zelenectide pevedotin, a bicycle toxin conjugate (BTC), which is in phase II clinical trials for the treatment of high nectin-4 expressing tumors; nuzefatide pevedotin (EphA2), a BTC that is in phase I/II clinical trials to treat Ephrin type A receptor 2 expressing tumor;

Related stock research

Other Healthcare stocks

Frequently asked questions

What is Bicycle Therapeutics Plc's market cap?

Bicycle Therapeutics Plc's market capitalization is USD 221.15M.

What does Bicycle Therapeutics Plc do?

Bicycle Therapeutics plc, a clinical-stage pharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom.